Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Liquid preparation of immunosuppressant monoclonal antibody

A monoclonal antibody and immunosuppressant technology, applied in the direction of antibodies, immunoglobulins, antibody medical components, etc., can solve the problems of many excipients and complicated operations

Pending Publication Date: 2021-07-09
LUNAN PHARMA GROUP CORPORATION
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Patents CN 102686216A and CN104399075A disclose anti-CD20 monoclonal antibody liquid preparations, which use many excipients and complicated operations

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Liquid preparation of immunosuppressant monoclonal antibody
  • Liquid preparation of immunosuppressant monoclonal antibody
  • Liquid preparation of immunosuppressant monoclonal antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Embodiment 1 investigates the influence of buffer system on the stability of liquid formulations

[0038] Combining the molecular characteristics of the anti-CD20 human-mouse chimeric monoclonal antibody, the buffer system commonly used in the protein preparation process, and the buffer range of the buffer system, after preliminary selection, citric acid / sodium citrate, acetic acid / sodium acetate, and disodium hydrogen phosphate were finally selected / sodium dihydrogen phosphate, histidine / histidine hydrochloride and disodium hydrogen phosphate / potassium dihydrogen phosphate buffer system were screened, and the preparation formula and test results are shown in Table 1 and Table 2, respectively.

[0039] Table 1 Liquid preparations of anti-CD20 human-mouse chimeric monoclonal antibody containing different buffer systems

[0040] serial number Element Formulation 1 Anti-CD20 Human Mouse Chimeric Monoclonal Antibody 20mg / mL 2 Polysorbate 80 0.003％...

Embodiment 2

[0045] Embodiment 2 investigates the influence of stabilizer on the stability of liquid preparation

[0046] The preparation formula and test results are shown in Table 3 and Table 4, respectively.

[0047] Table 3 contains anti-CD20 human-mouse chimeric monoclonal antibody liquid preparations with different stabilizers

[0048] serial number Element Formulation 1 Anti-CD20 Human Mouse Chimeric Monoclonal Antibody 20mg / mL 2 Histidine / Histidine Hydrochloride 15mM 3 stabilizer See Table 4 4 Polysorbate 80 0.03％ 5 Preparation pH 6.0

[0049] Table 4 SEC-HPLC aggregate results of anti-CD20 human-mouse chimeric monoclonal antibodies containing different stabilizers

[0050]

[0051]

[0052] Various liquid preparations added with different stabilizers were stored at 2-8°C, 25°C and 40°C respectively. The SEC-HPLC results showed that the increase of polymers and small molecules in the liquid preparations of 120mM and 240m...

Embodiment 3

[0053] Embodiment 3 investigates the influence of solubilizing agent on the stability of liquid preparation

[0054] The formulation formulations and stability test results are shown in Table 5 and Table 6, respectively. The liquid formulations of different formulations were subjected to 5 cycles of freezing and thawing and shaking for 3 days.

[0055] Table 5 Anti-CD20 human-mouse chimeric monoclonal antibody liquid preparations added with different concentrations of solubilizer

[0056] serial number Element Formulation 1 Anti-CD20 Human Mouse Chimeric Monoclonal Antibody 20mg / mL 2 Histidine / Histidine Hydrochloride 15mM 3 sucrose 120mM 4 Solubilizers See Table 6

[0057] Table 6 Freezing-thawing and shaking test results of anti-CD20 human-mouse chimeric monoclonal antibody liquid preparations added with different concentrations of solubilizer

[0058]

[0059]

[0060] Note: A-3D = shaking for 3 days, FT-5C = repeated f...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of pharmaceutical preparations, and particularly discloses a liquid preparation of an immunosuppressor monoclonal antibody, the liquid preparation provided by the invention comprises an anti-CD20 human-mouse chimeric monoclonal antibody, a buffer solution system, a stabilizer, a solubilizer and the like, the anti-CD20 human-mouse chimeric monoclonal antibody provided by the invention is better in stability and lower in aggregate, and the protein storage time is effectively prolonged.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, and in particular relates to a liquid preparation of an immunosuppressant monoclonal antibody. Background technique [0002] CD20 is an immunosuppressive receptor that acts as a surface antigen on B cells and appears from pre-B cells to mature B cells. Monoclonal antibodies targeting CD20 are referred to as anti-CD20 monoclonal antibodies. It has been reported that anti-CD20 monoclonal antibodies mainly kill tumors derived from B cells through three mechanisms: antibody-dependent cytotoxicity (ADCC); complement-dependent cytotoxicity (CDC); cell growth inhibition caused by antibody binding to CD20 molecules , cell cycle changes and apoptosis and other direct effects. Rituximab (trade name: MabThera) is a human-mouse chimeric monoclonal antibody, which has mouse-derived variable regions and human-derived constant regions. Biogen) research and development, global sales in 2018 reached ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61K9/08A61K47/26A61K47/18A61P35/00A61P35/02A61P29/00A61P19/02A61P37/02A61P9/14
CPCC07K16/2887A61K9/08A61K9/0019A61K47/26A61K47/183A61K39/39591A61P35/00A61P35/02A61P29/00A61P19/02A61P37/02A61P9/14C07K2317/24A61K2039/505
Inventor 张贵民赵丽丽刘金花刘忠
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com